Adia Nutrition, Inc. Announces Corporate Name Change to Adia Med, Inc. to Better Align with Its Regenerative Medicine and Biologics Business Model
Winter Park, Florida--(Newsfile Corp. - April 15, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company focused on regenerative medicine, stem cell therapies, and biologic products, today announced that it is in the process of changing its corporate name to Adia Med, Inc. The name change reflects the company's evolving business model, which has shifted significantly toward advanced medical treatments and biologics. Adia now operates through key divisions inclu
Soins de santé et hôpitaux, Santé
2026-04-15 8:30 AM EDT | Adia Nutrition Inc.
CareRx Corporation Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 15, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21-22, 2026, at the Metro Toronto Convention Centre. Puneet Khanna, President & Chief Executive Officer and Suzanne Brand, Ch
2026-04-15 7:30 AM EDT | CareRx Corporation
FendX Engages Galenvs for Pilot Scale-Up Manufacturing of Its Liquid Surface Coating
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, announces the signing of a statement of work ("SOW") dated April 14, 2026 with Galenvs Sciences Inc. ("Galenvs"), a Canadian contract manufacturing and service organization, to initiate pilot-scale manu
Technologies, Soins de santé et hôpitaux, Santé
2026-04-15 7:00 AM EDT | FendX Technologies Inc.
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through Month 12. In contrast, patients who switched to the placebo from Month 7 onwards experienced a reduction in treatment gains, demonstrating the importance of ongoing therapy. NDA a
Soins de santé et hôpitaux, Santé
2026-04-15 1:07 AM EDT | Cosmo Pharmaceuticals N.V.
Veritas Association Management Welcomes Society for the Advancement of Patient Blood Management
Chicago, Illinois--(Newsfile Corp. - April 14, 2026) - Veritas Association Management (Veritas) announces that it has been selected to provide full-service association management services to the Society for the Advancement of Patient Blood Management (SABM), a nonprofit organization dedicated to advancing patient blood management practices to improve clinical outcomes and patient safety worldwide. SABM is a multidisci
2026-04-14 4:40 PM EDT | Veritas Association Management
Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-14 10:00 AM EDT | Jones Healthcare Group
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum. The presentation will take place in front of a panel of expe
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-04-14 8:30 AM EDT | BioMark Diagnostics, Inc.
Fotonara and PhantomOmics Announce Revolutionary Partnership and "Good for All Humans" Initiative to Transform Affordable Housing into Sovereign Health Guardians
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Fotonara Inc., a pioneer in advanced manufacturing and sovereign smart building infrastructure, and PhantomOmics Inc., a visionary in proactive health technology, today announced a landmark global commercialization partnership. Together, the two Calgary-based tech innovators are launching the "Good for All Humans" initiative—a sweeping joint mission to make high-fidelity, preventative health monitoring a standard, low-cost uti
Technologies, Soins de santé et hôpitaux, Capteurs, Santé
2026-04-13 8:15 AM EDT | PhantomOmics Inc.
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of M
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-13 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
Voting Results of Cosmo's 2026 AGM
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record
Soins de santé et hôpitaux, Santé
2026-04-10 9:16 AM EDT | Cosmo Pharmaceuticals N.V.
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The present
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-09 7:00 AM EDT | Phio Pharmaceuticals Corp.
MyndTec Inc. Announces Inability to Secure Financing, Cessation of Operations and Evaluation of Strategic Alternatives Including Insolvency Proceedings
Mississauga, Ontario--(Newsfile Corp. - April 8, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company") announces that it has been unable to secure the additional financing required to continue operations. As previously disclosed, the Company's operations during 2024 and 2025 were substantially funded by its principal shareholder, Jim Anderson, through his participation in successive private placement offerings. Mr. Anderson has confirmed that he will not be mak
Technologies, Soins de santé et hôpitaux, Santé
2026-04-08 12:17 PM EDT | MyndTec Inc.
Trenchant Technologies Capital Corp. Announces Unwinding of Previous Limitless Quantum Acquisition
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has entered into a share exchange agreement dated March 18, 2026 and fully executed on April 5, 2026, (the "Share Exchange Agreement") providing for the unwinding of the Company's previously announced acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collective
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-04-08 11:46 AM EDT | Trenchant Technologies Capital Corp.
Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study
Winter Park, Florida--(Newsfile Corp. - April 8, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced a strategic partnership with a prominent clinic in Atlanta, Georgia. Adia Labs will serve as the exclusive supplier of regenerative products for the clinic's new Autism Spectrum Disorder (ASD) clinical study. This partnership is a key part of Adia Nutrition's 2026 plan to build solid scientific evidence for regenerative therapies that have the potenti
Soins de santé et hôpitaux, Santé
2026-04-08 8:30 AM EDT | Adia Nutrition Inc.
The Obesity Medicine Association Hosts Obesity Medicine 2026: The Heart of Obesity Care
Denver, Colorado--(Newsfile Corp. - April 8, 2026) - The Obesity Medicine Association (OMA), the nation's oldest medical society dedicated exclusively to obesity treatment, will host its annual conference, Obesity Medicine 2026: The Heart of Obesity Care, April 10-12 in San Diego, California. Bringing together more than 1,500 clinicians, researchers, and industry leaders, the conference highlights the latest science, clinical strategies, and innovations shaping the future of obesity med
Soins de santé et hôpitaux, Santé
2026-04-08 8:00 AM EDT | Obesity Medicine Association
LevelJump Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), a leading provider of teleradiology and diagnostic imaging services, today announced that it intends to complete a non-brokered private placement (the "Offering") of up to 15,000,000 common shares (the "Shares") of the Company at a price of $0.05 per Share, for gross proceeds of up to $750,000. Completion of the Offering is subject to the approval of the TSX Ventu
Soins de santé et hôpitaux, Santé
2026-04-07 6:18 PM EDT | LevelJump Healthcare Corp.
Canadian Ophthalmologists Highlight Seasonal Environmental Risks to Eye Health
Ottawa, Ontario--(Newsfile Corp. - April 7, 2026) - Ophthalmologists across Canada are observing the impact of seasonal environmental exposures — including ultraviolet (UV) radiation, wildfire smoke, and airborne allergens — on patients' ocular health and visual comfort. As these factors intensify during the spring and summer months, the Canadian Ophthalmological Society (COS) is underscoring the importance of awareness and preventive care to reduce both immediate irritation and l
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Les ophtalmologistes canadiens mettent en garde contre les risques environnementaux saisonniers pour la santé oculaire
Ottawa, Ontario--(Newsfile Corp. - 7 avril 2026) - Partout au pays, les ophtalmologistes constatent les effets des expositions environnementales saisonnières, notamment le rayonnement ultraviolet (UV), la fumée des feux de forêt et les allergènes en suspension dans l'air - sur la santé oculaire et le confort visuel des patients. À mesure que ces facteurs s'intensifient au printemps et à l'été, la Société canadienne d'ophtalmologie (SCO) s
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)